Walleye Capital LLC Uni Qure N.V. Transaction History

Walleye Capital LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.82 - $6.93 $287,214 - $412,944	-59,588 Reduced 42.33%	81,167 $422,000
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $83,194 - $122,205	14,777 Added 11.73%	140,755 $952,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $845,312 - $1.49 Million	125,978 New	125,978 $845,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $1.96 Million - $2.41 Million	104,642 New	104,642 $2.11 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $170,920 - $257,085	10,066 Added 45.49%	32,196 $604,000
Q2 2022 Aug 08, 2022	BUY	$13.15 - $20.45 $33,282 - $51,758	2,531 Added 12.91%	22,130 $413,000
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $284,969 - $421,378	19,599 New	19,599 $354,000
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $37,895 - $56,969	-841 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $206,411 - $381,611	-5,159 Reduced 85.98%	841 $40,000
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $255,879 - $499,276	-6,501 Reduced 52.0%	6,000 $236,000
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $595,976 - $928,418	11,296 Added 937.43%	12,501 $976,000
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $33,004 - $82,434	1,205 New	1,205 $72,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.